FDA Grants Priority Review to Palvella Therapeutics’ Qtorin
Palvella Therapeutics said the FDA granted priority review to Qtorin, which the company says could become the first FDA-approved therapy for microcystic lymphatic malformations.
Palvella Therapeutics said the FDA granted priority review to Qtorin, which the company says could become the first FDA-approved therapy for microcystic lymphatic malformations.